Papers/PMID:34332461
High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials.
Multiple sclerosis and related disorders2021The record
2 findings · 1 compound · 2 endpoints · 2 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
2 findings
biotin — no detected effect on adverse event occurrence (oral or enteral supplement)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Synthesized data on incidence of any AEs (RR 0.98; 95% CI 0.92-1.04; 3 trials; I2 = 0%) [high COE] and any serious AEs (RR 0.98; 95% CI 0.77-1.24; 3 trials; 889 participants; I2 = 0%) [moderate COE] were not significantly different between HDB and placebo groups.”
Quoted verbatim from High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials.. - Study
- meta-analysis
- Dose
- high-dose biotin at least 300 mg/day for at least three months
- Population
- Adults with multiple sclerosis (mostly progressive); three pooled randomized trials of oral high-dose biotin (at least 300 mg/day) as adjunctive treatment versus placebo
Effect 0.98 risk ratio, 95% CI 0.92 to 1.04
High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials.2021PMID:34332461Permalink
biotin — no detected effect on serious adverse event incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Synthesized data on incidence of any AEs (RR 0.98; 95% CI 0.92-1.04; 3 trials; I2 = 0%) [high COE] and any serious AEs (RR 0.98; 95% CI 0.77-1.24; 3 trials; 889 participants; I2 = 0%) [moderate COE] were not significantly different between HDB and placebo groups.”
Quoted verbatim from High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials.. - Study
- meta-analysis
- Participants
- 889
- Dose
- high-dose biotin at least 300 mg/day for at least three months
- Population
- Adults with multiple sclerosis (mostly progressive); three pooled randomized trials of oral high-dose biotin (at least 300 mg/day) as adjunctive treatment versus placebo
Effect 0.98 risk ratio, 95% CI 0.77 to 1.24
High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials.2021PMID:34332461Permalink